Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
About Author
More Stories
Porsche reports steep fall in orders from Europe and China
‘Fruit of the devil’: Hainan’s betel nut sellers suffer from stuttering economy
Will Trump’s tariff chaos be China’s gain in global trade wars?